Home / Search Results

Search Results

You searched for:

    Displaying results 1 - 20 of 21
  • 1
  • 2
  • »
Dr. Barbara Schmidtman highlights key findings from the 2022 ACCC Mini Z burnout survey, comparing results from the pre-pandemic 2019 to now.
In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
Put yourself first: this mantra is especially important today as we continue to grapple with the implications and fallout from the COVID-19 global pandemic.
COVID-19 has brought an unexpected, unwelcome, and unwanted disruption to oncology care, as it has to every other facet of life. ACCC has met this unprecedented pandemic, however, with its characteristic “how to” approach.
Assuming the ACCC presidency in March of 2020, just as the COVID-19 public health emergency went into effect, was certainly a dramatic way to enter office. That said, I am pleased with how much we have accomplished these last 12 months— despite the nationwide shutdown and ongoing pandemic.
Learn how genetic healthcare services have adapted to virtual care delivery, and what challenges face its widespread use after the COVID-19 pandemic is over.
On this episode of CANCER BUZZ, we discuss how healthcare providers and policymakers can work together to pave the future of telehealth beyond the current public health emergency.
ACCC applauds President Biden for renewing the Cancer Moonshot and setting the ambitious goals of reducing cancer mortality while improving the experience of patients living with cancer.
The Association of Community Cancer Centers (ACCC) commends Congress for including the extension of Medicare telehealth waivers in fiscal year 2022 omnibus legislation passed by both chambers this week.
Oncology Issues sat down with Dr. Schilsky to look back on his career and look forward to future research breakthroughs in this era of COVID-19 and beyond.
Leadership Panel Addresses Top Issues in Oncology Care BY CHRISTIAN G. DOWNS, JD, MHA In April, at the virtual 2020 Community Oncology Alliance Annual Conference, leaders across the cancer care community gathered online for a panel discussion of current events and policy priorities in oncology care. COVID-19 and its fallout on community cancer centers dominated the discussion, which was …
Oncology has always faced challenges, and cancer care teams are ever ready to change course and do what needs to be done to care for our patients and their families. But we do not have to do this alone. ACCC stands ready to assist.
As we turn the corner toward 2022, for oncology to drive equity forward: We need every member and every discipline, patient, leader, payer, industry partner, and innovator working together to provide the most equitable care possible in a sustainable way.
On Aug. 4, the Centers for Medicare & Medicaid Services (CMS) released its 2021 Hospital Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (PFS) proposed rules.
If enacted, patients with cancer across the country will benefit from increased access and new fiscal protections, including universal paid family leave.
Despite the availability of vaccines, drugs, and monoclonal antibodies, the healthcare field is more challenged than ever with the Omicron variant.
In my new role at ACCC as senior director, cancer care delivery and health policy, I am excited to take over writing this bimonthly column and communicating to our multidisciplinary membership about pertinent workforce, reimbursement, and cancer care delivery issues.
On November 20, the Centers for Medicare and Medicaid Services (CMS) released the Most Favored Nation (MFN) Model Interim Final Rule with Comment Period (IFC). While the Association of Community Cancer Centers (ACCC) acknowledges the effort of the Trump Administration to address rising drug costs, we strongly urge CMS to withdraw the MFN model. A policy that ties Medicare payment for outpatient drugs …
WASHINGTON, D.C. (December 4, 2020) – Today, the Pharmaceutical Research and Manufacturers of America (PhRMA), the Association of Community Cancer Centers (ACCC), the Global Colon Cancer Association (GCCA) and National Infusion Center Association (NICA) filed a lawsuit in the U.S. District Court for the District of Maryland asserting that the Most Favored Nation (MFN) Interim Final Rule exceeds the …
The Association of Community Cancer Centers (ACCC) announced today that Matt Devino, MPH has joined the organization as Director, Cancer Care Delivery and Health Policy.
    Displaying results 1 - 20 of 21
  • 1
  • 2
  • »